Theratechnologies has received correspondence from the U.S. Food and Drug Administration regarding the Company’s supplemental Biologics License Application for the F8 formulation of tesamorelin. The FDA has notified the Company that it is continuing its review of the application beyond the Prescription Drug User Fee Act goal date of January 22, 2024. Further information will be provided in due course.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on THTX:
- Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA
- Theratechnologies submits sBLA for Trogarzo IM method of administration to FDA
- Theratechnologies files $100M mixed securities shelf
- Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
- Theratechnologies announces FDA approval of Trogarzo IV push loading dose
